Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Strides’ Stelis Completes $195m Funding Rounds

Biopharmaceuticals Business Cites ‘Significant Interest From Marquee Investors’

Executive Summary

Strides says its Stelis biopharmaceuticals unit is now well-placed to pursue key growth initiatives after completing Series B and Series C funding rounds worth $195m that value the business at around $350m overall.

You may also be interested in...

Strides’ Stelis Makes Progress With Its Biosimilar Pipeline

Strides’ Stelis is taking its next steps in the biosimilars segment with teriparatide, insulin glargine and insulin aspart. After recently completing Series B and Series C funding rounds worth $195m, Stelis also said that it was onboarding customers for its CDMO services under multi-year contracts. The company has also signed its first vaccine supply contract with the Russian Direct Investment Fund for the Sputnik V vaccine.

Will Serum Institute Join Strides, Gland On The Sputnik V Flight?

While speculation mounts about Serum Institute being next in line for an RDIF partnership, Gland Pharma and Strides unit Stelis sign up to make COVID-19 vaccine Sputnik V. Part of the 550 million dose output tied up from India so far could be consumed domestically, but exports are a possibility as demand from European countries is set to jump.

CEO Sets Strides For Growth With Endo Execs

Appointing executives from Endo in key positions, Strides' CEO has set up a team to deliver growth, though the impact of ranitidine withdrawal and COVID-19 will defer a revenue target of $800m. Meanwhile, Stelis Biopharma signals a shift in focus from biologics development to CDMO opportunities and is poised for a stock exchange listing. 

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts